In an interview with PharmaShots, Douglas Onsi, CEO and President of Leap Therapeutics shares insights on the clinical data of DKN-01 along with its mechanism. He also highlights the company’s […]readmore
Tags : DKN-01
Shots: Leap to receive $3M up front, up to $132M development, regulatory, and sales milestones plus royalties on sales of product. BeiGene to get an exclusive option to license DKN-01, […]readmore